Cargando…
Inhibiting drug efflux transporters improves efficacy of ALS therapeutics
OBJECTIVE: Research identified promising therapeutics in cell models of Amyotrophic Lateral Sclerosis (ALS), but there is limited progress translating effective treatments to animal models and patients, and ALS remains a disease with no effective treatment. One explanation stems from an acquired pha...
Autores principales: | Jablonski, Michael R, Markandaiah, Shashirekha S, Jacob, Dena, Meng, Ni J, Li, Ke, Gennaro, Victoria, Lepore, Angelo C, Trotti, Davide, Pasinelli, Piera |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284125/ https://www.ncbi.nlm.nih.gov/pubmed/25574474 http://dx.doi.org/10.1002/acn3.141 |
Ejemplares similares
-
A mouse model with widespread expression of the C9orf72-linked glycine–arginine dipeptide displays non-lethal ALS/FTD-like phenotypes
por: Verdone, Brandie Morris, et al.
Publicado: (2022) -
Astrocytes expressing ALS‐linked mutant FUS induce motor neuron death through release of tumor necrosis factor‐alpha
por: Kia, Azadeh, et al.
Publicado: (2018) -
Targeting TNFα produced by astrocytes expressing amyotrophic lateral sclerosis‐linked mutant fused in sarcoma prevents neurodegeneration and motor dysfunction in mice
por: Jensen, Brigid K., et al.
Publicado: (2022) -
Glucose Hypometabolism Prompts RAN Translation and Exacerbates C9orf72-related ALS/FTD Phenotypes
por: Nelson, A.T., et al.
Publicado: (2023) -
ALS-linked mutant SOD1 damages mitochondria by promoting conformational changes in Bcl-2
por: Pedrini, Steve, et al.
Publicado: (2010)